Reading GALT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GALT free→Reading GALT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GALT free→QuarterlyIQ Insights · GALT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 15, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histor…
Results of Operations and Financial Condition. On March 31, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12, 2026, the Board of Directors of Galectin Therapeutics Inc. (the “Company”) appointed Dr. Henry Brem to serve as a member of the Board of Directors, effective immediately. Dr. Brem was not appointed pursuant to any arrangement or understanding with any other person. There are no transactions between Dr. Brem and the Company that would b…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 16, 2026, at the recommendation of the Company’s compensation committee, the Company’s board of directors approved a $300,000 cash retention bonus for the Company’s Chief Medical Officer, Dr. Khurram Jamil, and a $150,000 cash retention bonus for the Company’s Chief Financial Officer, Jack Callicutt. The retention bonuses will be paid in…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 10, 2026, Marc Rubin resigned from the Board of Directors of Galectin Therapeutics, Inc. (the “Company”). Mr. Rubin’s resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin…
Entry into a Material Definitive Agreement. On December 19, 2025, Galectin Therapeutics Inc. (the “Company”) and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “December 2025 Supplemental Line of Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the “Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the Line of Credit through January 31, 2027. Each…
Results of Operations and Financial Condition. On November 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the nine months ended September 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except f…
Results of Operations and Financial Condition. On August 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the his…
Entry into a Material Definitive Agreement. On July 8, 2025, Galectin Therapeutics Inc. (the “Company”) and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “July 2025 Supplemental Line of Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the “Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the Line of Credit through April 30, 2026. Each advance ma…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 8, 2025, at the recommendation of the Company’s compensation committee, the Company’s board of directors approved two additional compensation strategies for employees designed to ensure continued motivation and retention. All current employees will receive a cash bonus equal of their respective annual bonus targets if the Company enters int…
Results of Operations and Financial Condition. On May 15, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2025 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…
Results of Operations and Financial Condition. On March 31, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historic…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.